LigaChem Biosciences
Scope
Date
~
-
Bio & Pharma
Korean drugmakers close to commercializing COVID-19 vaccine, pill
South Korea’s biopharmaceutical companies are close to commercializing a COVID-19 vaccine and treatment pill as they are on the brink of compl...
Apr 25, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector
SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand it...
Mar 31, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience becomes first to win domestic COVID-19 vaccine contract
SK Bioscience Co. said it reached a deal with Korea’s disease control agency to supply 10 million doses of the country’s first experimen...
Mar 22, 2022 (Gmt+09:00)
language -
Earnings
SK Bioscience posts record earnings driven by COVID-19 vaccines
SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, has posted record 2021 revenue and operating profit, boosted by contrac...
Feb 08, 2022 (Gmt+09:00)
-
COVID-19
SK Bioscience to sell Novavax COVID-19 vaccine in Thailand, Vietnam
SK Bioscience Co., a biopharmaceutical unit of South Korea’s SK Group, said on Friday it has acquired non-exclusive rights to sell US-based No...
Dec 24, 2021 (Gmt+09:00)
language -
Shareholder activism
Activist fund again urges SK Chem to sell SK Bioscience stake
An activist fund has again urged South Korea’s SK Chemicals to sell part of its stake in SK Bioscience or buy back treasury shares and cancel ...
Dec 17, 2021 (Gmt+09:00)
-
Shareholder activism
SK Chem says no immediate plan to sell SK Bioscience stake
SK Chemicals Co., the top shareholder of South Korea's SK Bioscience Co., is not considering reducing its stake in the vaccine maker in the immediat...
Nov 02, 2021 (Gmt+09:00)
-
Biotech
JW Bioscience in pancreatic cancer biomarker deal with Immunovia
JW Bioscience Co., a subsidiary of South Korea’s JW Life Science Co., has signed a non-exclusive agreement to transfer its patented technology...
Sep 15, 2021 (Gmt+09:00)
language -
Markets
Activist fund urges SK Chemicals to sell part of SK Bioscience stake
A Singaporean activist fund has urged South Korea’s SK Chemicals to sell some of its shares in SK Bioscience Co., saying its corporate value h...
Sep 08, 2021 (Gmt+09:00)
-
Markets
MSCI adds SK Bioscience, SKIET, EcoPro BM to Korea Index
Global index provider Morgan Stanley Capital International (MSCI) added SK IE Technology Co. (SKIET), SK Bioscience Co. and EcoPro BM Co. to its K...
Aug 12, 2021 (Gmt+09:00)
-
COVID-19
SK Bioscience to kick off phase 3 vaccine trials
SK Bioscience Co. has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for phase 3 clinical trials of its COVID-19...
Aug 10, 2021 (Gmt+09:00)
language -
COVID-19
SK Bioscience secures up to $173.4 mn from CEPI for vaccine development
SK Bioscience Co. has secured additional funding for phase III clinical trial of GBP510, its COVID-19 vaccine candidate jointly developed with the I...
May 24, 2021 (Gmt+09:00)
-
COVID-19
SK Bioscience halts flu vaccine output to focus on COVID vaccines
South Korea’s SK Bioscience Co. is suspending production of SKYCellflu, an influenza vaccine, to focus on manufacturing COVID-19 vaccines inst...
Mar 30, 2021 (Gmt+09:00)
language -
IPOs
SK Bioscience debuts strong, up 160% from IPO price
SK Bioscience Co., a spin-off from the vaccine division of SK Chemicals, posted a strong debut on Kospi on Mar. 18, closing at 169,000 won a share, ...
Mar 18, 2021 (Gmt+09:00)
language -
IPOs
SK Bioscience IPO draws record-high demand from retail investors
South Korean vaccine maker SK Bioscience Co. has set a new record for initial public offering demand, raising around 63.6 trillion won ($56 billio...
Mar 11, 2021 (Gmt+09:00)
language -
IPOs
SK Bioscience’s $1.3 bn IPO generates $10 mn in underwriting fees
The initial public offering of SK Bioscience Co. was priced at the upper end of its price band of 65,000 won ($57.3) per share on Monday to raise 1....
Mar 08, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience attracts NPS, GIC in successful bookbuilding
South Korea-based SK Bioscience Co. has successfully concluded the bookbuilding for its initial public offering, attracting institutional investors ...
Mar 05, 2021 (Gmt+09:00)
language -
COVID-19
SK Bioscience eyes $900 mn annual sales from vaccine business
South Korea’s SK Bioscience Co. is looking to post 1 trillion won ($900 million) in annual revenue from its vaccine business as the biopharmac...
Feb 23, 2021 (Gmt+09:00)
language -
IPOs
Controversy surrounds SK Bioscience’s $1 bn IPO valuation
SK Bioscience Co., a spin-off of SK Chemicals Co.'s vaccine division, is set to list on the South Korean stock exchange on March 18 to raise up to $...
Feb 09, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience aims for March listing; enterprise value may reach $4.5 bn
South Korea-based SK Bioscience Co. is planning its trading debut next month on the country's main bourse, Kospi. The company's enterprise value is ...
Feb 08, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience begins listing process; enterprise value near $3 bn
South Korea’s SK Bioscience Co., set to enter clinical trials for its COVID-19 vaccine candidates, is expected to list on the Seoul main bours...
Dec 03, 2020 (Gmt+09:00)
-
COVID-19
SK Bioscience wins COVID-19 vaccine manufacturing order from US firm
SK Bioscience Co. Ltd. has secured a contract manufacturing organization (CMO) order for a new coronavirus vaccine candidate under development by the ...
Aug 14, 2020 (Gmt+09:00)